IP Library Granted Patent US 8,748,460
Granted Patent B2
US 8,748,460 · App. 13/761,583 · Granted Jun 10, 2014

Iminosugars and methods of treating togaviral diseases

Inventors: Urban Ramstedt (Bethesda, MD); Brennan Klose (Washington, DC); Nicole Zitzmann (Oxford, GB); Raymond A. Dwek (Oxford, GB); Terry D. Butters (Oxford, GB)
Assignees: United Therapeutics Corporation; The Chancellor, Masters and Scholars of the University of Oxford
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,748,460
App. No.
13/761,583
Granted
Jun 10, 2014
Kind
B2
Abstract

Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.

Claims (25)

1. A method of treating a disease or condition caused by or associated with a virus belonging to the Togaviridae family, the method comprising

administering to a subject in need thereof a compound of the formula,

or a pharmaceutically acceptable salt thereof, wherein R is either selected from substituted or unsubstituted alkyl groups, substituted or unsubstituted cycloalkyl groups, substituted or unsubstituted aryl groups, or substituted or unsubstituted oxaalkyl groups; or wherein R is

R 1 is a substituted or unsubstituted alkyl group;

X 1-5 are independently selected from H, NO 2 , N 3 , or NH 2 ;

Y is absent or is a substituted or unsubstituted C 1 -alkyl group, other than carbonyl; and

Z is selected from a bond or NH; provided that when Z is a bond, Y is absent, and provided that when Z is NH, Y is a substituted or unsubstituted C 1 -alkyl group, other than carbonyl; and wherein W 1-4 are independently selected from hydrogen, substituted or unsubstituted alkyl groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl groups.

2. The method of claim 1 , wherein R is a C8-C16 alkyl group.

3. The method of claim 2 , wherein each of W 1-4 is hydrogen.

4. The method of claim 3 , wherein the compound is N-nonyl-deoxynojirimycin or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein R is

6. The method of claim 5 , wherein each of W 1-4 is hydrogen.

7. The method of claim 5 , wherein X 1 is NO 2 and X 3 is N 3 .

8. The method of claim 5 , wherein each of X 2 , X 4 and X 5 is hydrogen.

9. The method of claim 5 , wherein the compound is N—(N-{4′-azido-2′-nitrophenyl}-6-aminohexyl)deoxynojirimycin or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the subject is a mammal.

11. The method of claim 1 , wherein the subject is a human being.

12. The method of claim 1 , wherein the virus is selected from Sindbis virus; Semliki Forest virus; O'nyong'nyong virus; Chikungunya virus; Mayaro virus; Ross River virus; Barmah Forest virus; Eastern equine encephalitis virus; Western equine encephalitis virus; Venezuelan equine encephalitis virus and Rubella virus.

13. The method of claim 1 , wherein the virus belongs to Genus Alphavirus.

14. The method of claim 1 , wherein the virus is Chikungunya virus.

15. The method of claim 1 , wherein the virus is Venezuelan equine encephalitis virus.

16. The method of claim 1 , wherein the disease or condition is selected from sindbis fever; O'nyong'nyong fever; Chikungunya disease; Ross River fever; Barmah Forest virus infection; Eastern equine encephalitis; Western equine encephalitis; Venezuelan equine encephalitis and Rubella.

17. The method of claim 1 , wherein the disease or condition is Chikungunya disease.

18. The method of claim 1 , wherein the disease or condition is equine encephalitis.

19. The method of claim 1 , wherein the disease or condition is Venezuelan equine encephalitis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2015
From: UNITED THERAPEUTICS CORPORATION
To: UNITHER VIROLOGY, LLC
Reel/Frame 036869/0480 →
Continuity (3)
Continuation 12813882 · Jun 11, 2010
Provisional Application 61186614 · Jun 12, 2009
Related Publication 20130150405A1 · Jun 13, 2013